#### PATENT APPLICATION

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q86673

Yoshikazu TAKAOKA, et al.

Appln. No.: National Stage Entry of PCT/JP03/11835

Confirmation No.: not yet assigned Group Art Unit: not yet assigned

Filed: March 10, 2005 Examiner: not yet assigned

For: NOVEL CRYSTALS OF TRIAZASPIRO [5.5] UNDECANE DERIVATIVE

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of each of the listed documents, in the ISR should accompany the papers received from the International Bureau. However, applicant will be glad to furnish copies upon request.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

DT06 Pac'd PCT 1 0 MAR 2005

# INFORMATION DISCLOSURE STATEMENT National Stage Entry of PCT/JP03/11835

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of the corresponding International Search Report citing such documents, indicating the degree of relevance found by the International Bureau.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

Registration No. 32,197

SUGHRUE MION, PLLC

Telephone: (202) 293-7060 Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373
CUSTOMER NUMBER

Date: March 10, 2005

# DT06 Pec'd PCT/PTO 1 0 MAR 2005

MODIFIED PTO/SB/08 A & B (06-03)

			MODIFIED F 10/36/06 A & B (00-03)		
, a		Com if Known 27193			
Substitute for Form 1449 A & B/PTO			National Stage Entry of		
TANDODA A PINONI DICCI OCUPE		Application Number	PCT/JP03/11835		
INFORMATION DISCLO		Confirmation Number	Not yet assigned		
STATEMENT BY APPLICANT		Filing Date	March 10, 2005		
_		First Named Inventor	Yoshikazu TAKAOKA		
(use as many sheets as neces	ssary)	Art Unit	Not yet assigned		
		Examiner Name	Not yet assigned		
Sheet 1 c	of 1	Attorney Docket Number	Q86673		
Sheet 1 c	of   1	Attorney Docket Number	U800/3		

U.S. PATENT DOCUMENTS						
Examiner Initials*		Document Number				
	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		US				
		US				
		US				
		US				
		US				
. 1		US				
		US				
		US				
		US				

FOREIGN PATENT DOCUMENTS							
	Cite	Cite F	oreign Patent Document		Publication Date	Name of Patentee or	Translation <sup>6</sup>
	No.1	Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation
		WO	03/035074	Al	5/1/2003	ONO PHARMACEUTICAL CO., LTD.	ļ
		WO	02/074770	A1	9/26/2002	ONO PHARMACEUTICAL CO., LTD.	
		wo	02/074770	Α	9/26/2002	ONO PHARMACEUTICAL CO., LTD	
		WO	01/040227	A1	6/7/2001	ONO PHARMACEUTICAL CO., LTD.	
							<del> </del>
							<u> </u>
	- N- F-2						
			<u> </u>				<u> </u>

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>	
		FORMAGGIO, F., "Nitroxyl peptides catalysts for enantioselective oxidations", Chemistry-A European Journal, (2002), Vol. 8, No.1, pages 84 to 93		
		International Search Report for PCT/JP03/11835 dated December 9, 2003		
			L	

Examiner Signature	Date Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.